- Home
- IKT vs CIK Comparison
IKT vs CIK Comparison
Compare IKT & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- CIK
- Stock Information
- Founded
- IKT 2008
- CIK 1987
- Country
- IKT United States
- CIK United States
- Employees
- IKT N/A
- CIK N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- CIK Finance/Investors Services
- Sector
- IKT Health Care
- CIK Finance
- Exchange
- IKT Nasdaq
- CIK Nasdaq
- Market Cap
- IKT 168.0M
- CIK 156.6M
- IPO Year
- IKT 2020
- CIK N/A
- Fundamental
- Price
- IKT $2.10
- CIK $2.83
- Analyst Decision
- IKT Buy
- CIK
- Analyst Count
- IKT 2
- CIK 0
- Target Price
- IKT $8.00
- CIK N/A
- AVG Volume (30 Days)
- IKT 111.4K
- CIK 115.4K
- Earning Date
- IKT 05-14-2025
- CIK 01-01-0001
- Dividend Yield
- IKT N/A
- CIK 9.03%
- EPS Growth
- IKT N/A
- CIK N/A
- EPS
- IKT N/A
- CIK N/A
- Revenue
- IKT N/A
- CIK N/A
- Revenue This Year
- IKT N/A
- CIK N/A
- Revenue Next Year
- IKT N/A
- CIK N/A
- P/E Ratio
- IKT N/A
- CIK N/A
- Revenue Growth
- IKT N/A
- CIK N/A
- 52 Week Low
- IKT $1.12
- CIK $2.50
- 52 Week High
- IKT $4.20
- CIK $3.19
- Technical
- Relative Strength Index (RSI)
- IKT 50.06
- CIK 52.88
- Support Level
- IKT $1.78
- CIK $2.81
- Resistance Level
- IKT $2.37
- CIK $2.83
- Average True Range (ATR)
- IKT 0.16
- CIK 0.03
- MACD
- IKT -0.00
- CIK 0.01
- Stochastic Oscillator
- IKT 54.70
- CIK 82.50
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations, and individuals.